M&A Deal Summary |
|
|---|---|
| Date | 2017-05-25 |
| Target | LifeStyles |
| Sector | Consumer Products |
| Buyer(s) |
Trustar Capital
Humanwell Healthcare |
| Deal Type | Divestiture |
| Deal Value | 600M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 1978 |
| PE ASSETS | 7.7B USD |
| Size | Mega |
| Type | Sector Agnostic |
Trustar Capital is the private equity arm of financial services/asset manager CITIC Group. Trustar Capital separates its private equity investment activity into three groups; China, Japan, and the US. In general, Trustar looks to invest in companies with 'strong franchises', with established brands and high barriers to entry. For US-based opportunities, the firm looks to leverage its connections in China. Broad areas of interest include niche manufacturing, consumer products, and business services. The Firm does not invest in start-ups or distressed businesses. Trustar Capital is based in Hong Kong.
| DEAL STATS | # |
|---|---|
| Overall | 30 of 52 |
| Sector (Consumer Products) | 2 of 5 |
| Type (Divestiture) | 1 of 5 |
| Country (Singapore) | 2 of 3 |
| Year (2017) | 2 of 3 |
| Size (of disclosed) | 4 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-05-18 |
Aavid Thermalloy
Concord, New Hampshire, United States Aavid, through its global network of manufacturing and design centers, provides a broad range of technologically advanced thermal management solutions for aerospace and defense, telecommunication, LED lighting, server, data center, consumer electronics, transportation, and industrial applications to customers all over the world. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-11-27 |
Wall Street English
Hong Kong, China Wall Street English is a provider of English language training to adults. Wall Street English was founded in 1972 and is based in Hong Kong, China. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1993 |
| Sector | Life Science |
| Employees | 17,676 |
| Revenue | 24.5B CNY (2023) |
Humanwell Healthcare is a fully integrated healthcare solution provider in Asia Pacific, North America, Europe and Africa. Founded in 1993 by a group of passionate college graduates, Humanwell has since transformed into a fully integrated healthcare solution provider. Humanwell has been active presence in over 10 countries and districts to date. Since its establishment, Humanwell has been endeavouring to bring safe and effective medicines to the world through the quality of its products and the integrity of its people. Humanwell Healthcare was founded in 1993 and is based in Wuhan, China.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Consumer Products) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Singapore) | 1 of 1 |
| Year (2017) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-06-13 |
Wuhan Biological Products Research Institute
Wuhan, China Wuhan Biological Products Research Institute Co. Ltd. develops, manufactures and commercialises plasma-derived products for the Chinese domestic market. This includes albumin, immunoglobulin (Ig) for IV injection, as well as several hyperimmune Ig products. The company also has an advanced pipeline of multiple coagulation factor products that it plans to launch in the coming years, including plasma-derived Factor VIII. In addition, Ruide owns four plasma collection centres and one manufacturing facility in Wuhan, Central China. |
Sell | $352M |
